Prime Medicine, Inc. Common Stock (PRME)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $949.85M
Last updated: Nov 17, 2026 at 11:06 AM ET
Prime Medicine, Inc. Common Stock (PRME) Earnings: Report Dates and Results
Prime Medicine, Inc. Common Stock (PRME) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Prime Medicine, Inc. Common Stock reported EPS of -$0.22, above the -$0.23 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PRME has an expected report date of Mar 1, 2027.
Earnings History
Of the 17 quarters below that had an estimate, PRME beat 5, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $4.21M, up 242.3% from $1.23M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.22 | -$0.23 | -$0.30 - -$0.19 | +4.35% | Beat | N/A | 14 | 1 up, 1 down | Nov 12, 2026 | $4.21M |
| Jun 30, 2026 | -$0.24 | -$0.24 | -$0.29 - -$0.18 | 0.00% | In line | N/A | 13 | 1 up, 1 down | Aug 6, 2026 | $1.15M |
| Mar 31, 2026 | -$0.28 | -$0.25 | -$0.28 - -$0.19 | -12.00% | Miss | N/A | 11 | 2 up, 2 down | May 7, 2026 | $856000 |
| Dec 31, 2025 | -$0.24 | -$0.26 | -$0.31 - -$0.19 | +6.90% | Beat | N/A | 11 | 2 up, 5 down | Mar 3, 2026 | $838000 |
| Sep 30, 2025 | -$0.32 | -$0.25 | -$0.33 - -$0.21 | -28.00% | Miss | N/A | 10 | 8 up, 0 down | Nov 7, 2025 | $1.23M |
| Jun 30, 2025 | -$0.41 | -$0.36 | -$0.42 - -$0.26 | -13.89% | Miss | N/A | 10 | 1 up, 0 down | Aug 7, 2025 | $1.11M |
| Mar 31, 2025 | -$0.40 | -$0.31 | -$0.35 - -$0.18 | -29.03% | Miss | N/A | 8 | 2 up, 1 down | May 8, 2025 | $1.45M |
| Dec 31, 2024 | -$0.31 | -$0.49 | N/A | +36.73% | Beat | N/A | 10 | 7 up, 1 down | Feb 28, 2025 | $2.18M |
| Sep 30, 2024 | -$0.44 | -$0.42 | -$0.48 - -$0.35 | -4.76% | Miss | N/A | 11 | 1 up, 0 down | Nov 12, 2024 | $209000 |
| Jun 30, 2024 | -$0.46 | -$0.39 | -$0.43 - -$0.37 | -17.95% | Miss | N/A | 12 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$0.44 | -$0.46 | -$0.57 - -$0.41 | +4.35% | Beat | N/A | 9 | 0 up, 0 down | May 10, 2024 | $591000 |
| Dec 31, 2023 | -$0.72 | -$0.51 | -$0.58 - -$0.44 | -41.18% | Miss | N/A | 8 | 0 up, 0 down | Mar 1, 2024 | $25.69M |
| Sep 30, 2023 | -$0.55 | -$0.46 | -$0.54 - -$0.39 | -19.57% | Miss | N/A | 7 | 0 up, 0 down | Nov 3, 2023 | N/A |
| Jun 30, 2023 | -$0.47 | -$0.42 | -$0.47 - -$0.39 | -11.90% | Miss | N/A | 6 | 0 up, 0 down | Aug 7, 2023 | N/A |
| Mar 31, 2023 | -$0.44 | -$0.41 | -$0.50 - -$0.37 | -7.32% | Miss | N/A | 4 | 1 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.56 | -$0.65 | -$1.59 - -$0.31 | +13.85% | Beat | N/A | 4 | 0 up, 0 down | Mar 9, 2023 | $5.21M |
| Sep 30, 2022 | -$1.61 | -$0.55 | N/A | -192.73% | Miss | N/A | N/A | N/A | Oct 21, 2022 | N/A |
| Mar 31, 2022 | -$0.32 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2022 | N/A |
| Sep 30, 2021 | -$0.24 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 20, 2021 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.37, after -$1.65 the year before. It was -$2.73 for the year ended Dec 31, 2022, the oldest of the 4 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.37 | N/A |
| Dec 31, 2024 | -$1.65 | N/A |
| Dec 31, 2023 | -$2.18 | N/A |
| Dec 31, 2022 | -$2.73 | N/A |
Frequently Asked Questions About PRME
When is Prime Medicine, Inc. Common Stock's next earnings date?
Prime Medicine, Inc. Common Stock's next earnings report is expected for Mar 1, 2027.
Did PRME beat earnings estimates last quarter?
Yes. Prime Medicine, Inc. Common Stock reported EPS of -$0.22 for the quarter ended Sep 30, 2026, above the -$0.23 estimate, a 4.35% surprise.
What EPS do analysts expect from PRME next quarter?
The consensus EPS estimate for Prime Medicine, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.23 from 17 analysts, with estimates from -$0.31 to -$0.04.
How often does PRME beat earnings estimates?
Prime Medicine, Inc. Common Stock beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -4.37%.
PRME pages: Overview, Earnings, Forecast, Financials, Competitors